Jonathan W. Lee

Pain Medicine
550 1st Ave
New York, NY 10016

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Corrigendum to Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression, Cancer Treatment and Research Communications 46 (2026) 101109.

Corrigendum to Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression, Cancer Treatment and Research Communications 46 (2026) 101109.

Journal: Cancer treatment and research communications
Published: May 03, 2026

Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression.

Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression.

Journal: Cancer treatment and research communications
Published: December 15, 2025

The impact of preoperative imaging strategies in EGFR-mutant non-small cell lung cancer: a multicenter retrospective review.

The impact of preoperative imaging strategies in EGFR-mutant non-small cell lung cancer: a multicenter retrospective review.

Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025

Protecting the front line: a cross-sectional survey analysis of the occupational factors contributing to healthcare workers' infection and psychological distress during the COVID-19 pandemic in the USA.

Protecting the front line: a cross-sectional survey analysis of the occupational factors contributing to healthcare workers' infection and psychological distress during the COVID-19 pandemic in the USA.

Journal: BMJ open
Published: October 22, 2020

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 25, 2020

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.

Journal: Journal of the National Cancer Institute
Published: October 31, 2017

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.

Journal: Cancer
Published: October 21, 2017

Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.

Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.

Journal: European journal of cancer (Oxford, England : 1990)
Published: August 27, 2017
Showing 1-8 of 8

Last Updated: 09/26/2026